There are currently 61 active clinical trials seeking participants for Atopic Dermatitis research studies. The states with the highest number of trials for Autism participants are California, Florida, Texas and Ontario.
A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)
NCT05717920
Recruiting
A Phase 2, multicenter, adaptive 2-part clinical trial designed to evaluate the safety and efficacy of ADX-629 alone and in combination with standard-of-care in adults with atopic dermatitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: Bexley Dermatology Research, Bexley, Ohio
Conditions: Atopic Dermatitis
Register for Updates
Natural History and Genetics of Food Allergy and Related Conditions
NCT02504853
Recruiting
Background: - About 15 million Americans have a food allergy. Because there are no cures or effective prevention or treatment for food allergies, researchers want to learn more about them. Objective: - To learn more about the causes and effects of food allergy and related conditions. Eligibility: People ages 2 99 who have food allergy and/or a related genetic or other condition Their relatives Healthy relatives and volunteers Design: Participants will have at least 3 visits over 1 2 years... Read More
Gender:
All
Ages:
Between 1 day and 99 years
Trial Updated:
04/18/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Food Allergy, Loeys-Dietz Syndrome, Atopic Dermatitis, Eosinophilic Esophagitis
Register for Updates
A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis
NCT06119529
Recruiting
The main purpose of this study is to evaluate the safety and tolerability of LY3872386 in healthy participants and participants with atopic dermatitis. The safety of prednisone is also evaluated in healthy participants. Blood tests will be performed to investigate how the body processes the LY3872386 following single and multiple dosing in healthy participants and participants with atopic dermatitis. Blood tests will also be performed to investigate how the body processes the prednisone in healt... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/18/2024
Locations: CenExel ACT, Anaheim, California +3 locations
Conditions: Healthy, Atopic Dermatitis
Register for Updates
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
NCT06238817
Recruiting
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: Lynn Institute of the Ozarks, Little Rock, Arkansas +105 locations
Conditions: Atopic Dermatitis
Register for Updates
A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)
NCT05398445
Recruiting
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
04/17/2024
Locations: Cahaba Dermatology and Skin Health Center, Birmingham, Alabama +201 locations
Conditions: Atopic Dermatitis
Register for Updates
A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe AD
NCT06224192
Recruiting
The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneous using devices for injection at home.
Gender:
All
Ages:
Between 12 years and 100 years
Trial Updated:
04/17/2024
Locations: Long Beach Research Institute, Long Beach, California +13 locations
Conditions: Atopic Dermatitis
Register for Updates
Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism
NCT04455906
Recruiting
This protocol is primarily looking to see if the IL-4Ra R576 polymorphism is associated with increased clinical, immunological and microbial markers of disease activity in patients with Atopic dermatitis.
Gender:
All
Ages:
Between 6 years and 65 years
Trial Updated:
04/17/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Atopic Dermatitis
Register for Updates
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05559359
Recruiting
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to <18 years of age with moderate-to-severe atopic dermatitis (AD).
Gender:
All
Ages:
Between 6 months and 17 years
Trial Updated:
04/16/2024
Locations: Clinical Research Center of Alabama, Birmingham, Alabama +95 locations
Conditions: Atopic Dermatitis, Eczema
Register for Updates
A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
NCT05372419
Recruiting
The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atopic dermatitis (AD) and skin of color.
Gender:
All
Ages:
12 years and above
Trial Updated:
04/15/2024
Locations: Total Skin and Beauty Dermatology Center, PC, Birmingham, Alabama +46 locations
Conditions: Atopic Dermatitis
Register for Updates
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT05911841
Recruiting
The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (AD).
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
04/15/2024
Locations: Johnson Dermatology, Fort Smith, Arkansas +63 locations
Conditions: Atopic Dermatitis
Register for Updates
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05735483
Recruiting
The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to <18 years of age with moderate-to-severe atopic dermatitis
Gender:
All
Ages:
Between 6 months and 18 years
Trial Updated:
04/14/2024
Locations: Clinical Research Center of Alabama, Birmingham, Alabama +93 locations
Conditions: Atopic Dermatitis, Eczema
Register for Updates
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
NCT05958407
Recruiting
The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. This will be judged by a range of assessments that rate the severity and extent of atopic hand eczema and its symptoms, as well as general health status and quality of life. The trial will last for up to 40 weeks. There will be up to 15 visits, 3 of which will be conducted by phone. The first part of the trial is called a screening period and will last up to... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/10/2024
Locations: LEO Pharma Investigational Site, Birmingham, Alabama +52 locations
Conditions: Atopic Dermatitis, Atopic Hand Eczema
Register for Updates